View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
pharma services oehler|3 September 2019

Market Access

For reimbursement of a medicinal product by the health insurance providers in Switzerland, the Swiss Federal Office of Public Health (BAG) requires proof of the efficacy, appropriateness and cost-effectiveness of the medicinal product for marketing approval. We provide our expertise for this purpose.

Strategic consultation

Benefit from our experience to quickly achieve reimbursement for your medicinal products: • Definition of the adequate price strategy (foreign price comparison, therapeutic cross-comparison) • Review and, if necessary, optimisation of the current pricing strategy • Negotiations with the authorities (Swiss Federal Office of Public Health (BAG))

Operational support

We would be happy to support you in the areas of: • Literature searches for the relevant decision criteria, including evaluation • Documentation of the effectiveness, appropriateness and economic viability • Drafting of applications for health insurance reimbursement • Review of acceptance criteria every three years or after patent expiry

This white paper highlights what it takes to bring a drug to the Swiss market, including the marketing authorisation application MAA), preapproval and launch preparation...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology